【摘要】：目的:通過檢測鈣網(wǎng)蛋白(calreticulin,CRT)和B細(xì)胞受體相關(guān)蛋白31(B-cell receptor-associated protein 31,BAP31)在非小細(xì)胞肺癌組織、癌旁組織以及正常肺組織中的表達(dá)情況,并分析兩者在非小細(xì)胞肺癌患者中與年齡、性別、吸煙、病理類型、淋巴結(jié)轉(zhuǎn)移以及臨床分期的關(guān)系,進(jìn)而探索CRT和BAP31在非小細(xì)胞肺癌發(fā)生、發(fā)展、浸潤以及轉(zhuǎn)移過程中所起的作用,同時(shí),通過對二者在非小細(xì)胞肺癌中表達(dá)相關(guān)性的分析,探討二者在非小細(xì)胞肺癌的發(fā)生、發(fā)展過程中是否具有協(xié)同或拮抗作用。方法:選取西南醫(yī)科大學(xué)附屬第一醫(yī)院2015年1月至2015年12月胸外科手術(shù)切除并且術(shù)后均經(jīng)病理診斷明確為非小細(xì)胞肺癌的標(biāo)本60例,其中選取鱗癌30例,腺癌30例,并選取相對應(yīng)的癌旁組織(至少距腫瘤邊緣5cm以上)30例(隨機(jī)選取,其中包括鱗癌17例,腺癌13例)為檢測對象,所選病例均具備完整的臨床診斷和治療資料,并且排除其他肺部疾病及嚴(yán)重的心、肝、腎和代謝性疾病,取得待測標(biāo)本前患者均未進(jìn)行放療、化療、分子靶向治療及其他針對惡性腫瘤的治療;另外選取正常肺組織30例作為對照組。通過免疫組化方法檢測非小細(xì)胞肺癌組織、癌旁組織、正常肺組織中CRT和BAP31的表達(dá)情況,并分析兩指標(biāo)在非小細(xì)胞肺癌患者中的表達(dá)與年齡、性別、吸煙、病理分型、淋巴結(jié)轉(zhuǎn)移、臨床分期的關(guān)系,進(jìn)一步分析兩指標(biāo)在非小細(xì)胞肺癌中的表達(dá)是否具有相關(guān)性。結(jié)果:1.CRT在非小細(xì)胞肺癌組織中表達(dá)的陽性率為88.33%,明顯高于其在正常肺組織和癌旁肺組織中的陽性表達(dá)率(6.67%和13.33%),差異具有統(tǒng)計(jì)學(xué)意義(P0.01),但是正常肺組織和癌旁組織的表達(dá)差異不具有統(tǒng)計(jì)學(xué)意義(P0.05),CRT的陽性表達(dá)與非小細(xì)胞肺癌患者的性別、年齡、吸煙情況及病理分型無明顯相關(guān)性,而與淋巴結(jié)轉(zhuǎn)移和臨床分期相關(guān)。2.BAP31在非小細(xì)胞肺癌組織中的陽性表達(dá)率為83.33%,明顯高于其在正常肺組織和癌旁肺組織中的陽性表達(dá)率(3.33%和6.67%),差異具有統(tǒng)計(jì)學(xué)意義(P0.01),但是正常肺組織和癌旁組織的表達(dá)差異不具有統(tǒng)計(jì)學(xué)意義(P0.05),BAP31的陽性表達(dá)與患者的性別、年齡、吸煙情況、病理分型無明顯相關(guān)性,其與淋巴結(jié)轉(zhuǎn)移和不同TNM分期也無明顯相關(guān)性。3.CRT與BAP31在非小細(xì)胞肺癌組織中的表達(dá)無明顯相關(guān)性。結(jié)論:1.CRT在非小細(xì)胞肺癌中呈高表達(dá),其陽性表達(dá)與淋巴結(jié)轉(zhuǎn)移和分期相關(guān),可能參與非小細(xì)胞肺癌的發(fā)生、發(fā)展過程。2.BAP31在非小細(xì)胞肺癌中呈高表達(dá),其陽性表達(dá)與患者年齡、性別、病理分型、淋巴結(jié)轉(zhuǎn)移和TNM分期無明顯相關(guān)性。3.CRT與BAP31在非小細(xì)胞肺癌組織中的表達(dá)無明顯相關(guān)性,需更大樣本的研究加以明確證實(shí)。
[Abstract]:Objective: to investigate the expression of calmodulin (calreticulin,CRT) and B cell receptor-associated protein 31 (B-cell receptor-associated protein 31) in non-small cell lung cancer (NSCLC), paracancerous tissues and normal lung tissues. The relationship between age, sex, smoking, pathological type, lymph node metastasis and clinical stage in patients with non-small cell lung cancer (NSCLC) was analyzed to explore the role of CRT and BAP31 in the occurrence and development of NSCLC. The role of invasion and metastasis in the process of invasion and metastasis. At the same time, through the analysis of the correlation between the expression of both in non-small cell lung cancer, to explore whether they have synergistic or antagonistic action in the occurrence and development of non-small cell lung cancer. Methods: from January 2015 to December 2015, 60 cases of non-small cell lung cancer (NSCLC) were selected from the first affiliated Hospital of Southwest Medical University, including 30 cases of squamous cell carcinoma and 30 cases of adenocarcinoma. Thirty cases (including 17 cases of squamous cell carcinoma and 13 cases of adenocarcinoma) corresponding to adjacent tissues (at least more than 5cm from the edge of the tumor) were selected as subjects. All the selected cases had complete clinical diagnosis and treatment data. Other lung diseases and severe heart, liver, kidney and metabolic diseases were excluded. Patients were not treated with radiotherapy, chemotherapy, molecular targeted therapy and other treatment for malignant tumor before obtaining the specimen. In addition, 30 cases of normal lung tissue were selected as control group. The expression of CRT and BAP31 in non-small cell lung cancer (NSCLC) tissues, paracancerous tissues and normal lung tissues were detected by immunohistochemical method, and the expression and age, sex, smoking and pathological classification of the two markers in NSCLC patients were analyzed. The relationship between lymph node metastasis and clinical stage, and further analysis of the expression of the two markers in non-small cell lung cancer (NSCLC). Results: the positive rate of 1.CRT expression in non-small cell lung cancer tissues was 88.33, which was significantly higher than that in normal lung tissues and adjacent lung tissues (6.67% and 13.33%). The difference was statistically significant (P0.01), but there was no significant difference in the expression of), CRT between normal lung tissues and para-cancerous tissues (P0.05) and the sex and age of patients with non-small cell lung cancer (NSCLC). There was no significant correlation between smoking and pathological classification, but there was no correlation between smoking and lymph node metastasis and clinical stage. The positive expression rate of 2.BAP31 in non-small cell lung cancer was 83.33. The positive expression rate was significantly higher in normal lung tissues and adjacent lung tissues (3.33% vs 6.67%), and the difference was statistically significant (P0.01). However, there was no significant difference in the expression of BAP31 between normal lung tissues and paracancerous tissues (P0.05). There was no significant correlation between the positive expression of BAP31 and sex, age, smoking status, pathological type of patients. There was no significant correlation between the expression of 3.CRT and BAP31 in non-small cell lung cancer (NSCLC) and lymph node metastasis and different TNM stages. Conclusion: 1.CRT is highly expressed in non-small cell lung cancer, and its positive expression is related to lymph node metastasis and staging, which may be involved in the occurrence and development of non-small cell lung cancer. 2.BAP31 is highly expressed in non-small cell lung cancer. There was no significant correlation between the positive expression and age, sex, pathological type, lymph node metastasis and TNM staging. There was no significant correlation between the expression of 3.CRT and BAP31 in non-small cell lung cancer tissues, which needed to be confirmed by larger samples.
【學(xué)位授予單位】：西南醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 施博文;喬文亮;韓玉棟;胡海洋;陳s，

本文編號：2301381